Skip to main content
OpenTrials
Completed

NCT Number: NCT04399577

Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Warts DNA Virus Infections Infections Papillomavirus Infections Skin Diseases Skin Diseases, Infectious Skin Diseases, Viral Skin and Connective Tissue Diseases Tumor Virus Infections Virus Diseases

Age range

9 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Zagazig University Faculty of Medicine

Zagazig, Sharqia Province, 44519, Egypt

About this study

39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic multiple cutaneous

Exclusion criteria

  • Hypersensitivity to Candida antigen
  • Fever
  • Immunosuppressive disorders
  • Previous wart therapy in the last month

Treatment and study plan

candida antigen

Biological

Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention

Primary outcomes

  1. Resolution of warts

    Time frame: 12 weeks

    100% clearance of warts

Secondary outcomes

  1. Recurrence

    Time frame: 6 months

    Reappearance of warts

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
May 22, 2020
Registry last updated
May 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.